Blood Disorders & Hematology Clinical Trials Update: Week 18, 2026

Published May 1, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

This Phase 3 trial is investigating two antibody treatments, rituximab and mosunetuzumab, for people with low tumor burden follicular lymphoma. The study involves 600 participants in the United States and aims to find out if mosunetuzumab can offer a treatment that is either more effective or easier to tolerate than the current option, rituximab. Results from this trial could help shape future treatment choices for patients with this type of lymphoma.

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This Phase 3 trial is testing the addition of inotuzumab ozogamicin to standard chemotherapy for patients with high-risk B-cell acute lymphoblastic leukemia and related blood cancers. The study includes both children and adults who are newly diagnosed and is happening at many locations worldwide. If successful, this treatment could target cancer cells more effectively and might reduce the amount of chemotherapy needed, potentially improving outcomes and quality of life.

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

This trial compares a new antibody treatment called epcoritamab with standard chemotherapy in people whose diffuse large B-cell lymphoma has returned or did not respond to previous treatment. The study is currently active but not enrolling new patients, with results expected after several years. This research could offer a new option for patients who have limited choices due to the challenges of their disease.

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

This Phase 3 trial is testing brentuximab vedotin combined with chemotherapy in children and young adults with advanced Hodgkin lymphoma. Recruiting across multiple countries, it focuses on patients with specific advanced stages of the disease. The goal is to improve survival outcomes and provide a more effective treatment option for those facing higher-risk lymphoma.

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

This large Phase 3 trial is exploring whether adding blinatumomab to chemotherapy improves treatment for patients newly diagnosed with B-lymphoblastic leukemia or lymphoma, including those with Down syndrome. With over 6,700 participants worldwide, the study seeks to enhance disease control through this targeted approach. Although it is not currently recruiting, the findings may lead to better therapies for this patient group.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.